ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 23 filers reported holding ASCENDIS PHARMA A/S in Q2 2016. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $1,100,000 | +166.3% | 8,175 | +205.5% | 0.14% | +100.0% |
Q3 2020 | $413,000 | +36.8% | 2,676 | +23.1% | 0.07% | +97.1% |
Q4 2019 | $302,000 | +73.6% | 2,174 | -83.4% | 0.04% | +250.0% |
Q2 2016 | $174,000 | -49.9% | 13,100 | -29.9% | 0.01% | -54.5% |
Q1 2016 | $347,000 | – | 18,700 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |